Zoetis earns license for Cytopoint skin therapyJanuary 4, 2017Veterinary drug maker Zoetis Inc. in December received a U.S. Department of Agriculture license for Cytopoint, which the Parsippany, N.J., company described as the first monoclonal antibody (mAb) therapy approved “to help provide sustained control of the clinical signs associated with atopic dermatitis in dogs.”
SPONSORED CONTENTImprove their microbiome, improve quality of lifeWith 70% of a dog’s immune system in the GI tract, you need confidence in their microbiome support — which is why Hill’s developed ActivBiome+. + Learn More
